查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447058

到 2030 年小分子标靶癌症治疗市场预测：按类型、应用和地区分類的全球分析

Small Molecule Targeted Cancer Therapy Market Forecasts to 2030 - Global Analysis By Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球小分子标靶癌症治疗市场规模将达825亿美元，预计2030年将达到1,479亿美元，预测期内复合年增长率为8.7%。

小分子药物比高分子药物更容易渗透细胞，并能有效抑制癌细胞生存所必需的蛋白质和酵素的活性。

小分子药物是指製药业的一个部分，专门开发和商业化专门针对癌细胞并使用小分子抑制其生长的药物。这些治疗方法透过抑制参与癌症生长、进展和转移的特定分子发挥作用，与传统化疗相比，提供更精确、更有针对性的治疗方法。

据FDA称，Cetuximab单抗等单株抗体的半衰期（3.1至7.8天）比Gefitinib等小分子药物的半衰期（48小时）长得多。

癌症发生率增加

不同人口和地区的癌症发生率不断增加，增加了对有效治疗方案的需求。透过特异性针对癌细胞中的分子变化，小分子标靶治疗可以抑制癌细胞增殖或诱导细胞死亡，同时对健康细胞的伤害最小，为癌症治疗提供了一种有前景的途径。此外，化疗等传统治疗方法通常会产生使人衰弱的副作用，从而增加了对更有针对性和毒性较小的治疗方法的需求。

开发成本高

开发针对特定癌细胞的小分子药物需要广泛的研究、临床试验和监管核准，所有这些都需要高昂的成本。确定适当的分子标靶、设计化合物、优化功效和确保安全的复杂过程需要大量的财务投资。然而，严格的监管要求和漫长的核准时间进一步增加了整体开发成本。对于缺乏财务资源的中小型生技公司和新兴企业来说，高成本是进入市场的主要障碍。

技术进步

高通量筛检、分子建模和计算化学等最尖端科技能够识别和设计小分子，从而提高针对癌症靶点的特异性和功效。分析技术的进步有助于准确表征候选药物并优化其药物动力学和动态特性。此外，药物输送系统的创新，包括奈米技术和标靶药物输送，透过提高肿瘤渗透性和减少脱靶效应，提高了小分子药物的治疗指数。

有限的生物标誌物

生物标记是生物过程或治疗反应的可测量指标，在识别适合标靶治疗的患者方面发挥关键作用。针对某些癌症和标靶治疗的生物标记的可用性通常是有限的。这种限制阻碍了准确选择标靶治疗最有效的患者，导致治疗结果不佳并可能限制市场成长。因此，生物标记的缺乏限制了癌症标靶药物的功效，并且还透过减少符合这些治疗条件的患者数量来阻碍市场成长。

COVID-19 的影响：

医疗保健服务和资源的中断转移了癌症治疗的注意力和资源，导致诊断和治疗启动的延迟。新的小分子标靶疗法的临床试验面临中断或推迟，阻碍了新药的开发和核准。供应链中断和行动限制进一步影响了现有治疗药物的製造和分销，导致患者获得治疗的短缺和延误。然而，医疗保健系统和患者的经济负担也影响了这些治疗方法的负担能力和利用。

蛋白酪氨酸激酶抑制剂领域预计在预测期内规模最大

由于其独特的作用机制和针对各种癌症类型的功效，蛋白酪氨酸激酶抑制剂预计将在预测期内获得最大份额。蛋白酪氨酸激酶抑制剂部分将在预测期内占据最大的市场份额，因为这些抑制剂针对特定的蛋白酪氨酸激酶，这些酶在涉及癌细胞生长和增殖的信号传导途径中发挥重要作用。蛋白酪氨酸激酶抑制剂的精确标靶性可最大程度地减少对健康细胞的损害，从而比传统化疗产生更少的副作用。此外，疗效提高、毒性降低的新型 TKI 的市场开拓扩大了各种癌症患者的治疗选择，进一步推动了市场成长。

预计黑色素瘤细分市场在预测期内复合年增长率最高

预计黑色素瘤领域在预测期内将出现显着增长。黑色素瘤是一种皮肤癌，其发生率在全球范围内显着增加，推动了对有效治疗方法的需求。小分子标靶治疗透过特异性针对参与癌症生长和进展的分子来提高对抗黑色素瘤的精确度，与传统治疗方法。此外，研究进展导致新型小分子药物的开发，这些药物针对黑色素瘤中涉及的特定基因突变和途径，扩大了患者的治疗选择。这些因素正在推动该细分市场的成长。

比例最高的地区：

随着癌症治疗越来越多地根据患者独特的分子特征进行定制，预计亚太地区将占据最大的市场份额，这被认为是个人化医疗。针对癌症患者的特定小分子可能会实现更个人化和精确的治疗计划，并考虑到每个病例的特殊性。随着基因组序列测定技术的进步，找到与特定癌症相关的罕见遗传异常和生物标记将变得更加容易。此外，该领域丰富的遗传资料使製药公司能够开发与特定基因谱相关的高度标靶化的药物，从而提高治疗效果和精确度。

复合年增长率最高的地区：

随着医疗保健提供者更加了解癌症治疗中标标靶治疗的益处和有效性，并更有可能向患者推荐这些疗法，预计亚太地区在预测期内将出现盈利成长。这种认知将导致更多地采用特异性针对癌细胞的小分子标靶疗法，同时最大限度地减少对健康细胞的损害。此外，该地区的医疗保健提供者随时了解支持标靶治疗的最新进展和临床证据，使他们能够识别适合这些治疗的患者并根据个人需求量身定制治疗方法。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球小分子标靶癌症治疗市场：依类型

  • 蛋白酪氨酸激酶抑制剂
  • 小分子药物偶联物
  • 其他类型

第六章 全球小分子标靶癌症治疗市场：依应用分类

  • 乳癌
  • 多发性骨髓瘤
  • 黑色素瘤
  • 淋巴瘤
  • 摄护腺癌
  • 其他用途

第七章全球小分子标靶癌症治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第八章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第九章 公司简介

  • Abbott Laboratories
  • Amgen
  • AstraZeneca
  • Bayer HealthCare AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cytokinetics Inc
  • Genentech
  • GlaxoSmithKline plc
  • Hospira Inc
  • Novartis
Product Code: SMRC25319

According to Stratistics MRC, the Global Small Molecule Targeted Cancer Therapy Market is accounted for $82.5 billion in 2023 and is expected to reach $147.9 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Small molecule drugs can penetrate cells more easily than larger molecules, allowing them to effectively inhibit the activity of proteins and enzymes critical for cancer cell survival.

It refers to the segment of the pharmaceutical industry dedicated to developing and commercializing drugs specifically designed to target and inhibit the growth of cancer cells through small molecules. These therapies work by interfering with specific molecules involved in the growth, progression, and spread of cancer, thereby offering more precise and targeted treatment options compared to traditional chemotherapy.

According to the FDA, the half life of monoclonal antibodies like cetuximab (3.1-7.8 days) is much longer than those of small-molecule agents like gefitinib (48 hours).

Market Dynamics:

Driver:

Increasing incidence of cancer

With cancer rates on the rise across various demographics and geographies, there is a growing demand for effective treatment options. Small molecule targeted therapies offer promising avenues for cancer treatment by specifically targeting molecular alterations in cancer cells, thereby inhibiting their growth or inducing cell death with minimal harm to healthy cells. Additionally, as traditional treatments like chemotherapy often come with debilitating side effects, the demand for more targeted and less toxic therapies is increasing.

Restraint:

High development costs

Developing small molecule drugs tailored to target specific cancer cells involves extensive research, clinical trials, and regulatory approvals, all of which incur substantial expenses. The intricate process of identifying suitable molecular targets, designing compounds, optimizing their efficacy, and ensuring their safety demands substantial financial investments. However, the rigorous regulatory requirements and lengthy approval timelines further escalate the overall development costs. For smaller biotechnology companies or startups with limited financial resources, these high costs present a considerable barrier to entry into the market.

Opportunity:

Technological advancements

Cutting-edge technologies such as high-throughput screening, molecular modeling, and computational chemistry enable the identification and design of small molecules with enhanced specificity and efficacy against cancer targets. Advances in analytical techniques facilitate the precise characterization of drug candidates, optimizing their pharmacokinetic and pharmacodynamic properties. Moreover, innovations in drug delivery systems, including nanotechnology and targeted drug delivery, enhance the therapeutic index of small molecule drugs by improving their tumor penetration and reducing off-target effects.

Threat:

Limited biomarkers

Biomarkers, which are measurable indicators of biological processes or responses to treatment, play a crucial role in identifying suitable patients for targeted therapies. The availability of biomarkers specific to certain types of cancer or targeted therapies is often limited. This limitation hampers the precise selection of patients who would benefit most from small molecule targeted therapies, leading to suboptimal treatment outcomes and potentially limiting market growth. Therefore, the lack of biomarkers limits the efficacy of targeted cancer medicines and also prevents market growth by reducing the number of patients that are eligible for these treatments.

Covid-19 Impact:

Disruptions in healthcare services and resources diverted attention and resources away from cancer treatment, leading to delays in diagnosis and initiation of therapy. Clinical trials for new small molecule targeted therapies faced interruptions or postponements, hindering the development and approval of new drugs. Supply chain disruptions and restrictions on movement further affected the manufacturing and distribution of existing therapies, causing shortages and delays in treatment access for patients. However, financial strains on healthcare systems and patients also impacted the affordability and utilization of these therapies.

The tyrosine kinase inhibitors segment is expected to be the largest during the forecast period

Due to their unique mechanism of action and effectiveness in treating various types of cancers. These inhibitors target specific tyrosine kinases, which are enzymes that play a crucial role in the signaling pathways involved in cancer cell growth and proliferation, Tyrosine Kinase Inhibitors segment is expected to hold the largest share during the projection period. Their precision targeting minimizes damage to healthy cells, leading to fewer adverse effects compared to traditional chemotherapy. Additionally, the development of novel TKIs with improved efficacy and reduced toxicity profiles has expanded treatment options for patients with different types of cancers, further driving market growth.

The melanoma segment is expected to have the highest CAGR during the forecast period

Melanoma segment is estimated to have the considerable growth over the forecast period. Melanoma, a type of skin cancer, has seen a substantial rise in incidence globally, driving the demand for effective treatments. Small molecule targeted therapies offer precision in combating melanoma by specifically targeting molecules involved in cancer growth and progression, resulting in enhanced efficacy and reduced side effects compared to traditional treatments. Additionally, advancements in research have led to the development of novel small molecule drugs tailored to target specific genetic mutations and pathways implicated in melanoma, expanding the therapeutic options available to patients. These elements are enhancing the segmental growth.

Region with largest share:

Because treatments for cancer are increasingly being customized to a patient's unique molecular profile, a phenomenon recognized as personalized medicine, the Asia Pacific region is expected to hold the largest share of the market during the projected period. Targeting specific small molecules in cancer patients may allow for more individualized and accurate treatment plans that take into account the particulars of their individual cases. As genome sequencing technology develops, it becomes simpler to find uncommon genetic anomalies and biomarkers connected to certain cancers. Furthermore, pharmaceutical companies can create highly targeted medications that are linked to certain genetic profiles due to the wealth of genetic data available in the area, improving treatment efficacy and precision.

Region with highest CAGR:

As healthcare providers become more knowledgeable about the benefits and effectiveness of targeted therapy in cancer treatment, they are more likely to recommend it to their patients, Asia Pacific region is estimated to witness profitable growth throughout the extrapolated period. This awareness leads to greater adoption of small molecule targeted therapies, which are designed to specifically target cancer cells while minimizing damage to healthy cells. Additionally, as healthcare providers in the region stay updated on the latest advancements and clinical evidence supporting targeted therapies, they become better equipped to identify suitable patients for these treatments and tailor therapy regimens to individual needs.

Key players in the market

Some of the key players in Small Molecule Targeted Cancer Therapy market include Abbott Laboratories, Amgen, AstraZeneca, Bayer HealthCare AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cytokinetics Inc, Genentech, GlaxoSmithKline plc, Hospira Inc and Novartis.

Key Developments:

In February 2024, Novartis to acquire cancer-centric MorphoSys for $2.9 bln. Novartis will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances.

In February 2024, Erasca, Inc., a precision oncology company, has entered into clinical trial collaboration and supply agreements with pharmaceutical giant Novartis to advance the development of a new cancer treatment.

Types Covered:

  • Tyrosine Kinase Inhibitors
  • Small Molecule Drug Conjugates
  • Other Types

Applications Covered:

  • Breast Cancer
  • Multiple Myeloma
  • Melanoma
  • Lymphoma
  • Prostate Cancer
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Small Molecule Targeted Cancer Therapy Market, By Type

  • 5.1 Introduction
  • 5.2 Tyrosine Kinase Inhibitors
  • 5.3 Small Molecule Drug Conjugates
  • 5.4 Other Types

6 Global Small Molecule Targeted Cancer Therapy Market, By Application

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Multiple Myeloma
  • 6.4 Melanoma
  • 6.5 Lymphoma
  • 6.6 Prostate Cancer
  • 6.7 Other Applications

7 Global Small Molecule Targeted Cancer Therapy Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Abbott Laboratories
  • 9.2 Amgen
  • 9.3 AstraZeneca
  • 9.4 Bayer HealthCare AG
  • 9.5 Boehringer Ingelheim GmbH
  • 9.6 Bristol-Myers Squibb
  • 9.7 Cytokinetics Inc
  • 9.8 Genentech
  • 9.9 GlaxoSmithKline plc
  • 9.10 Hospira Inc
  • 9.11 Novartis

List of Tables

  • Table 1 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 4 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 5 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 6 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 7 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 8 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 9 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 10 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 11 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 12 Global Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 13 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 14 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 15 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 16 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 17 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 18 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 20 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 21 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 22 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 23 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 24 North America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 27 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 28 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 29 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 30 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 31 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 32 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 33 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 34 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 35 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 36 Europe Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 37 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 38 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 39 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 40 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 41 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 42 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 43 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 44 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 45 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 46 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 47 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 48 Asia Pacific Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 49 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 51 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 52 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 53 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 54 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 55 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 56 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 57 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 58 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 59 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 60 South America Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 61 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 63 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Tyrosine Kinase Inhibitors (2021-2030) ($MN)
  • Table 64 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Small Molecule Drug Conjugates (2021-2030) ($MN)
  • Table 65 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 66 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 67 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 68 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 69 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 70 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 71 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 72 Middle East & Africa Small Molecule Targeted Cancer Therapy Market Outlook, By Other Applications (2021-2030) ($MN)